» Articles » PMID: 9398471

Effects of Different Schedules of MPTP Administration on Dopaminergic Neurodegeneration in Mice

Overview
Journal Exp Neurol
Specialty Neurology
Date 1997 Dec 17
PMID 9398471
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Although a valuable 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of human Parkinson's disease has been developed, our knowledge of the course of nigral degeneration remains fragmentary. Experimental factors which could possibly influence the destructive process must be taken into account. To evaluate the impact of experimental design, we compared the effects of different schedules of injection of the same cumulative dose of MPTP, in mice, by measuring tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta. Massive injection of the total dose over 1 day (4 injections of 20 mg/kg) destroyed more dopaminergic neurons than did the long-term daily injections of a lower dose of MPTP (20 injections of 4 mg/kg). This suggests that different schedules of administration of MPTP might induce different mechanisms of neuronal death. These mechanisms need to be better understood if chronic models of intoxication that replicate the evolution of human Parkinson's disease more precisely are to be developed.

Citing Articles

Transient dystonia correlates with parkinsonism after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in nonhuman primates.

Norris S, Tian L, Williams E, Perlmutter J Dystonia. 2023; 2.

PMID: 37711667 PMC: 10501383. DOI: 10.3389/dyst.2023.11019.


Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease.

Santoro M, Fadda P, Klephan K, Hull C, Teismann P, Platt B J Neurochem. 2022; 164(2):121-142.

PMID: 36184945 PMC: 10098710. DOI: 10.1111/jnc.15699.


Heterogeneity of dopamine release sites in health and degeneration.

Lebowitz J, Khoshbouei H Neurobiol Dis. 2019; 134:104633.

PMID: 31698055 PMC: 6980674. DOI: 10.1016/j.nbd.2019.104633.


Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease.

Canerina-Amaro A, Pereda D, Diaz M, Rodriguez-Barreto D, Casanas-Sanchez V, Heffer M Front Neurosci. 2019; 13:382.

PMID: 31068782 PMC: 6491821. DOI: 10.3389/fnins.2019.00382.


β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Mittal S, Bjornevik K, Im D, Flierl A, Dong X, Locascio J Science. 2017; 357(6354):891-898.

PMID: 28860381 PMC: 5761666. DOI: 10.1126/science.aaf3934.